Showing results (81-90 of 102) with videos related to
Sort By:
Pageof 11
Journal of the National Comprehensive Cancer Network : JNCCN|April 6, 2011
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastomaDavid A Reardon, Scott Turner, Katherine B Peters, et al.Neuro-Oncology|March 18, 2009
Phase I trial of temozolomide plus O6-benzylguanine 5-day regimen with recurrent malignant gliomaJennifer A Quinn, Sara Xiaoyin Jiang, David A Reardon, et al.Neuro-Oncology|March 25, 2008
Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant gliomaDavid A Reardon, Annick Desjardins, James J Vredenburgh, et al.Journal of Neuro-Oncology|September 23, 2011
Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningiomaDavid A Reardon, Andrew D Norden, Annick Desjardins, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|March 26, 2003
4-hydroperoxycyclophosphamide--purged peripheral blood stem cells for autologous transplantation in patients with acute myeloid leukemiaDavid A Rizzieri, Jeffrey T Talbot, Gwynn D Long, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2009
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant gliomaJennifer A Quinn, Sara Xiaoyin Jiang, David A Reardon, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 4, 2009
Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiformeJennifer A Quinn, Sara Xiaoyin Jiang, James Carter, et al.Journal of Neuro-Oncology|January 25, 2007
Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomasAnnick Desjardins, Jennifer A Quinn, James J Vredenburgh, et al.Plos One|March 3, 2012
A pilot study of IL-2Rα blockade during lymphopenia depletes regulatory T-cells and correlates with enhanced immunity in patients with glioblastomaJohn H Sampson, Robert J Schmittling, Gary E Archer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 6, 2010
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastomaJohn H Sampson, Amy B Heimberger, Gary E Archer, et al.Pageof 11